==Hycroft Mining (HYMC): 6-year performance

Hycroft is a U.S.-based gold and silver exploration and development company focused on its large open-pit Hycroft Mine in northern Nevada. It is not currently a producing operator in the traditional sense (active mining paused earlier, with focus on exploration, technical studies, and potential restart/development).

Hycroft Mining Holding Corporation (Nasdaq: HYMC) went public via a SPAC (special purpose acquisition company) process.

• SPAC IPO (as Mudrick Capital Acquisition Corporation): Priced around February 7–12, 2018. It raised approximately $200 million by offering units (including overallotment) at $10.00 per unit. The SPAC was formed by distressed-debt investor Jason Mudrick to target post-bankruptcy businesses.
• Business combination / de-SPAC: Completed on May 29, 2020, with Hycroft Mining. The combined company began trading as Hycroft Mining Holding Corporation under the ticker HYMC on the Nasdaq on Mon 1June 20.

Sector: Basic Materials

Industry: Gold

Full Time Employees: 51

HQ: Winnemucca, Nevada

https://www.hycroftmining.com

==StableCoinX (USDE) : 2-month performance,

StablecoinX Inc., a stablecoin infrastructure company, focuses on the Ethena digital dollar ecosystem. It offers infrastructure services, stablecoin middleware software, and stablecoin distribution services. The company is based in Frisco, Texas.

Sector: Financial Services

Industry: Capital Markets

https://stablecoinx.com

StablecoinX completed its public market debut on June 26, 2026, via a business combination with the special purpose acquisition company (SPAC) TLGY Acquisition Corp. Its Class A common stock trades on Nasdaq under the ticker symbol USDE. 

Public Listing Details

Transaction Date: June 26, 2026 (following the closure of the merger with TLGY Acquisition Corp. on June 25, 2026).
Exchange / Ticker: Nasdaq Capital Market under USDE (Class A shares) and USDEW (warrants).
Core Focus: Functioning as a public stablecoin infrastructure firm and treasury vehicle centered around the Ethena Labs ecosystem, holding a multi-year treasury strategy in ENA governance tokens.
Leadership: Led by CEO Edward Chen

Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65

Founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 

Headquartered in Cambridge, MA
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.

==Silvercrest Asset Management (SAMG)

Silvercrest Asset Management Group Inc. completed its initial public offering on June 27, 2013, trading on the NASDAQ under the ticker symbol SAMG.

Founded in 2002, the New York-based wealth management firm focuses on ultra-high-net-worth individuals, families, and institutional investors.

IPO and Offering Details

Date: June 27, 2013 (effective June 26, 2013)
Exchange / Ticker: NASDAQ: SAMG
Shares Offered: ~4.8 million shares
Price Range: $12 to $14 per share
Capital Raised: ~$62 million
Lead Underwriters: Sandler O’Neill + Partners and Raymond James

Initial Delay: Silvercrest initially filed for a $55 million IPO in September 2012, but formally withdrew it in November 2012 citing unfavorable market valuations.

==RoboStrategy (BOT) : 2-month performance

 RoboStrategy, Inc. debuted on the public market on May 11, 2026, listing on the NASDAQ under the ticker symbol BOT. Rather than a standard operating company IPO, it launched as a specialized closed-end investment fund.

• https://robostrategy.co/

Fund Structure and Purpose

Vehicle Type: Closed-end management investment company.
Core Objective: Provides public market and retail investors access to private, pre-IPO, and public robotics and physical AI companies.
Investment Access: Targets high-profile robotics startups that have historically been restricted to venture capital funds.

Portfolio Holdings

Featured Startups: Includes private sector leaders such as Figure AI, Apptronik, Standard Bots, Dyna Robotics, and Dexmate.
Strategy: Focuses on a high-conviction portfolio of 20 to 30 positions concentrated on hardware, humanoids, and physical artificial intelligence.

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

==Parabilis Medicines (PBLS) began trading on the Nasdaq on Wed 10 June 26

Parabilis Medicines is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them.  

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 145
• Founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 
• Formerly known as Fog Pharma
• Headquartered in Cambridge, Massachusetts
• https://parabilismed.com/

===Quantinuum (QNT) began trading on the Nasdaq on Thur 4 June 26

 

Quantinuum is the world’s largest integrated quantum computing company, formed in late 2021 by the merger of Honeywell Quantum Solutions (hardware expertise, trapped-ion technology) and Cambridge Quantum (software, algorithms, and quantum cybersecurity).Key Facts

• Headquarters: Broomfield, Colorado (US), with major operations in Cambridge, UK, and additional sites in Germany, Japan, and elsewhere.
• Employees: Approximately 450–680 (sources vary; includes 370+ scientists and engineers, with a high proportion holding advanced degrees).
• Leadership: CEO Rajeeb Hazra; Ilyas Khan (founder of Cambridge Quantum) serves as Chief Product Officer.
• Status: Privately held until recently; it completed a major IPO in early June 2026 on Nasdaq (ticker QNT), raising significant capital at a multi-billion-dollar valuation amid strong demand. Honeywell remains a major backer.

TechnologyQuantinuum specializes in trapped-ion quantum computers, widely regarded as among the highest-performing in the industry due to high gate fidelities, full qubit connectivity, and support for mid-circuit measurements.

• H-Series (e.g., System Model H2): Features up to 56 fully connected qubits, record quantum volumes (a holistic performance metric exceeding 2 million in some reports), and >99.99% single-qubit gate fidelity. It has demonstrated milestones like the first fully fault-tolerant universal gate set.
• Roadmap: Accelerated push toward universal, fault-tolerant quantum computing by 2030, with next-generation systems like Apollo (targeting 100+ qubits). Emphasis on scalable, high-fidelity hardware combined with error correction.
• Software & Full-Stack: Includes TKET (open-source compiler), InQuanto (chemistry-focused), Quantum Origin (quantum-enhanced cybersecurity/randomness), and the Nexus platform for cloud access, emulation, and hybrid workflows. Strong integration across hardware, software, and applications.

Access is available via cloud (e.g., Azure Quantum) and direct subscriptions, with emulators for development.

Applications and Focus AreasThe company targets commercial and scientific breakthroughs in:

• Materials discovery and computational chemistry
• Drug discovery and biology
• Cybersecurity (quantum-resistant solutions)
• Optimization, AI, finance, and energy (e.g., collaborations with bp on wave physics/seismic imaging)
• Hybrid quantum-classical computing for industry use cases

It emphasizes "science-led, enterprise-driven" solutions and has partnerships with entities like RIKEN, Mitsubishi Electric, NVIDIA, JPMorgan, Synopsys, and others.